🇺🇸 SITAGLIPTIN AND METFORMIN HCL in United States

SITAGLIPTIN AND METFORMIN HCL (SITAGLIPTIN, METFORMIN HYDROCHLORIDE) regulatory status in United States.

Marketing authorisations

FDA

  • Status: approved

FDA

  • Application: ANDA217829
  • Marketing authorisation holder: INVENTIA HEALTHCARE LIMITED
  • Local brand name: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
  • Indication: TABLET, EXTENDED RELEASE
  • Status: approved

Read official source →

FDA

  • Application: ANDA212869
  • Marketing authorisation holder: SINOTHERAPEUTICS INC
  • Local brand name: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
  • Indication: TABLET, EXTENDED RELEASE
  • Status: approved

Read official source →

FDA

  • Application: ANDA218971
  • Marketing authorisation holder: MANKIND PHARMA LTD
  • Local brand name: SITAGLIPTIN AND METFORMIN HCL
  • Indication: TABLET
  • Status: approved

Read official source →

FDA

  • Application: ANDA215411
  • Marketing authorisation holder: INVENTIA HEALTHCARE LIMITED
  • Local brand name: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
  • Indication: TABLET
  • Status: approved

Read official source →

Other Other approved in United States

Frequently asked questions

Is SITAGLIPTIN AND METFORMIN HCL approved in United States?

Yes. FDA has authorised it; FDA has authorised it; FDA has authorised it.

Who is the marketing authorisation holder for SITAGLIPTIN AND METFORMIN HCL in United States?

MANKIND PHARMA LTD is the originator. The local marketing authorisation holder may differ — check the official source linked above.